ArticleImmunoTargets and therapy2026
Effectiveness and Safety of Eculizumab in Highly Active AChR+gMG and Its Therapeutic Response in Different Subtypes of gMG.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eculizumab had been approved for anti-acetylcholine receptor antibody-positive (AChR+) refractory myasthenia gravis (MG), but its effect on the broader group of highly active generalized myasthenia gravis (gMG) in clinical practice has not been fully uncovered. Methods: We conduct a retrospective multi-center cohort study with prospectively collected data to explore the effectiveness and safety of eculizumab in highly active patients in clinical practice. Results: Thirty-three patients from 4 research centers were included in our study treated with eculizumab. This study contains 1 early onset MG (EOMG), 13 late-onset MG (LOMG), and 19 thymoma-associated MG (TAMG) patients. At week 12, the mean Myasthenia Gravis Activities of Daily Living (MG-ADL) score decreased by 7.97 ± 3.96 points and Quantitative Myasthenia Gravis (QMG) score decreased by 12.88±5.82 points,13 (40%) patients achieved minimal symptom expression (MSE) and 78.7% patients were ADL responders (the improvement of MG-ADL score ≥3 points and lasted for at least 4weeks). The improvement was sustained for 24 weeks. Overall, four patients had experienced myasthenic crisis (MC), and the time to wean from mechanical ventilation (MV) was 6.33±3.21 days. In muscle subdomains analysis, QMG score decreased more obviously in the ocular group (66%) and bulbar group (49%) than in other muscle groups at week 4. Moreover, subgroup analysis showed that the TAMG and LOMG groups exhibited a similar degree of therapeutic effect in symptom control and ADL response. The mean prednisone dose was reduced by 12.84±20.36 mg/day at week 24. Patients in our study showed well tolerance to eculizumab, and none of them experienced meningococcal infections. Conclusion: Our study confirmed the safety and effectiveness of eculizumab in highly active gMG patients with reducing steroid dose. TAMG and MC may be suitable indications for treatment with eculizumab. All the muscle groups achieved improvements, especially for the extraocular muscles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.